EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Baseline Neutrophil-to-Lymphocyte Ratio and Efficacy of SGLT2 Inhibition with Empagliflozin on Cardiac Remodelling

Raj Verma, Michael Moroney, Makoto Hibino, Cyril David Mazer, Kim A Connelly, Andrew T Yan, Adrian Quan, Hwee Teoh, Subodh Verma, Pankaj Puar

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14351 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Raj Verma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Coronary Artery Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation and plays a critical role in the assessment and prognosis in patients with heart failure. The EMPA-HEART CardioLink-6 trial demonstrated that patients with type 2 diabetes (T2D) and coronary artery disease (CAD) treated with a sodium–glucose transport protein 2 inhibitor for 6 months experienced regression in left ventricular mass. Given this, we evaluated the relationship of baseline NLR and cardiac reverse remodelling in the entire cohort of this trial. Methods and results A total of 97 individuals were randomized to receive empagliflozin (10 mg/day) or placebo for 6 months. The primary outcome of the trial was change in left ventricular mass indexed to body surface area (LVMi) from baseline to 6 months as measured by cardiac magnetic resonance imaging. In our analysis, the cohort was stratified above and below an NLR level of 2. To assess the treatment effect on the 6 month change in NLR, we used a linear model adjusting for baseline differences in NLR [analysis of covariance (ANCOVA)] that included an interaction term between the baseline NLR and treatment. To assess the treatment effect on the 6 month change in LVMi in each of the subgroups divided by baseline NLR, we used an ANCOVA adjusting for baseline differences in LVMi that included an interaction term between the subgroups and treatment. The results of the regression models were summarized as adjusted differences with two-sided 95% confidence intervals (CIs). Patients who exhibited an elevated baseline NLR demonstrated higher LVMi and left ventricular end-diastolic volume indexed to body surface area than those with a lower NLR. In patients with an NLR < 2 and NLR ≥ 2, the adjusted difference in LVMi between the empagliflozin- and placebo-treated patients was −2.98 g/m2 (95% CI: −6.18 to 0.22 g/m2) (P value = 0.067) and −4.43 g/m2 (95% CI: −8.50 to −1.11 g/m2), respectively (Pinteraction = 0.60).

Conclusions

Empagliflozin treatment is associated with consistent reductions in LVMi in patients with T2D and CAD independent of baseline NLR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCoronary Artery DiseaseHumansSodium-Glucose Transporter 2Ventricular RemodelingNeutrophilsBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

InflammationLeft ventricular reverse remodellingNLRSGLT2iType 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2empagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario, Canada.
  • School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Anesthesia, St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario, Canada.
  • Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
  • Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Verma, R., Moroney, M., Hibino, M., Mazer, C. D., Connelly, K. A., Yan, A. T., Quan, A., Teoh, H., Verma, S., & Puar, P. (2023). Baseline Neutrophil-to-Lymphocyte Ratio and Efficacy of SGLT2 Inhibition with Empagliflozin on Cardiac Remodelling. ESC Heart Failure. https://doi.org/10.1002/ehf2.14351

Vancouver

Verma R, Moroney M, Hibino M, Mazer CD, Connelly KA, Yan AT, et al. Baseline Neutrophil-to-Lymphocyte Ratio and Efficacy of SGLT2 Inhibition with Empagliflozin on Cardiac Remodelling. ESC Heart Failure. 2023. doi:10.1002/ehf2.14351

BibTeX
@article{Verma2023,
  author = {Verma, Raj and Moroney, Michael and Hibino, Makoto and Mazer, Cyril David and Connelly, Kim A and Yan, Andrew T and Quan, Adrian and Teoh, Hwee and Verma, Subodh and Puar, Pankaj},
  title = {Baseline Neutrophil-to-Lymphocyte Ratio and Efficacy of SGLT2 Inhibition with Empagliflozin on Cardiac Remodelling},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14351}
}
Kostenlos starten →